Immuneering presented new circulating tumor DNA (ctDNA) data at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego on April 20, 2026. The data, derived from 123 patients treated with atebimetinib, showed that acquired MAPK‑pathway alterations were rare, reinforcing the drug’s ability to limit resistance in RAS‑mutant tumors.
The patient‑level ctDNA analysis confirms that resistance mechanisms are uncommon, supporting atebimetinib’s Deep Cyclic Inhibition platform that delivers durable tumor shrinkage while maintaining a favorable tolerability profile. The findings provide independent evidence that the drug’s clinical benefit is sustained and that resistance mechanisms are uncommon.
Management highlighted that the data supports atebimetinib’s first‑line pancreatic cancer strategy and suggests broader applicability in other RAS‑mutant malignancies. CEO Ben Zeskind said, "Atebimetinib is designed to promote survival by three mechanisms: shrinking tumors durably, preserving body mass by counteracting muscle wasting, and maintaining performance status by maximizing tolerability." CSO Brett Hall added, "Deep Cyclic Inhibition of MEK avoids the continuous selective pressure that typically drives tumors to become resistant to treatment via reactivation of the MAPK pathway. This, combined with atebimetinib's tolerability profile, has the potential to improve depth and durability of response in a broad range of cancers, starting with first‑line pancreatic cancer."
The presentation will inform the ongoing Phase 3 MAPKeeper 301 trial, which is expected to dose its first patient in mid‑2026. The data provides independent, patient‑level evidence that atebimetinib’s clinical benefit is sustained and that resistance mechanisms are uncommon, potentially strengthening Immuneering’s competitive position in the high‑value pancreatic cancer market.
Immuneering’s financial backdrop remains solid, with a Q4 2025 net loss attributable to common stockholders of $11.6 million and a full‑year 2025 loss of $56.0 million, compared with $18.1 million and $61.0 million in the same periods in 2024. The company ended 2025 with $217.0 million in cash, cash equivalents, and marketable securities, giving it a runway into 2029.
While the report did not disclose the exact frequency of acquired MAPK‑pathway alterations, the characterization of them as rare underscores the potential durability of atebimetinib’s therapeutic effect and supports the company’s strategy to expand beyond pancreatic cancer.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.